National Pharmaceutical Regulatory Agency Ministry of Health Malaysia Lot 36, Jalan Profesor Diraja Ungku Aziz, 46200 Petaling Jaya, Selangor. Tel. No.: 03-7883 5491 Website: http://www.npra.gov.my/			For Official Use Only		
			Application No.:		
			ate Received:		
		Da	ate Completed:		
PARTA APPLICANT/PRO	DUCT REGISTRATION	HOLDER INFO	RMATION		
Name of Applicant:					
Name of Product Registration Hole (PRH):	der				
Address:					
Company/Business Registration N	lumber:				
Contact Telephone: Can be more than 1 number		Email Addres	SS:		
Issuance of Invoice (Company name and Address) *if different from PRH					
PART B FOREIGN MANUE	ACTURER INFORMATIC	N			
Name:					
Address:					
Country:	Previous Date of Ir NPRA (if any):	spection by			
GPS Coordinate: Latitud			Longitude		
PART C PURPOSE OF APP	PLICATION (Please tick the	appropriate box)	·	•	
Product Registration (N	lew)	Cha	ange of Site to Exist	ing Manufa	acturer
Product Registration (R	(enewal)	Oth	ers (Specify):		
PART D FACILITY AND PR	ODUCT INFORMATION				
Category of products to be		(Please mark 🖾 t	ne appropriate box)		
inspected (choose only ONE)	Sterile		Non-sterile		
	Large Volume Liqu	id 🗌	Tablet		Cream/Ointment
	Small Volume Liqu	id 🗌	Capsule		Solution
Product Dosage Form	Liquid for external	use	Powder		Suspension
	Liquid for internal u	ise	Granule		Suppository
Other (Specify):					
	Penicillin or Cepha	losporin			Hormone
Type of Product:	Cytotoxic or Anti-C	Cytotoxic or Anti-Cancer preparation			Steroid
	Biologic (e.g. vaccines	Biologic (e.g. vaccines, blood products, biotechnology products)*			None of the above
*For Biological product: (choose only ONE)	Drug Substance		Drug Product		

PARTE(The following documents MUST be submitted together with this application)providedUse On1.Payment of Processing Fee RM5,000.002.A copy of Company/Business Registration Certificate (for Product Registration Holder)3.List of Building/Workshop/Line/Unit and dosage forms manufactured in each Building/Workshop/Line/Unit to be inspected4.Details of new products to be registered in Malaysia (Annex I) </th <th></th>						
2. A copy of Company/Business Registration Certificate (for Product Registration Holder) 3. List of Building/Workshop/Line/Unit and dosage forms manufactured in each Building/Workshop/Line/Unit to be inspected 4. Details of new products to be registered in Malaysia (Annex I) 5. Details of existing registered products for change of manufacturing site (Annex II) 6. Details of product registration holder and their respective registered products (Annex III) 7. Details of product registration holder and their respective registered products (Annex IV) 8. Site Master File 9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
3. List of Building/Workshop/Line/Unit and dosage forms manufactured in each Building/Workshop/Line/Unit to be inspected 4. Details of new products to be registered in Malaysia (Annex I) 5. Details of existing registered products of renewal of product registration (Annex II) 6. Details of existing registered products for change of manufacturing site (Annex III) 7. Details of product registration holder and their respective registered products (Annex IV) 8. Site Master File 9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
3. Building/Workshop/Line/Unit to be inspected 4. Details of new products to be registered in Malaysia (Annex I) 5. Details of existing registered products of renewal of product registration (Annex II) 6. Details of existing registered products for change of manufacturing site (Annex III) 7. Details of product registration holder and their respective registered products (Annex IV) 8. Site Master File 9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
5. Details of existing registered products of renewal of product registration (Annex II) 6. Details of existing registered products for change of manufacturing site (Annex III) 7. Details of product registration holder and their respective registered products (Annex IV) 8. Site Master File 9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
6. Details of existing registered products for change of manufacturing site (Annex III) 7. Details of product registration holder and their respective registered products (Annex IV) 8. Site Master File 9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
7. Details of product registration holder and their respective registered products (Annex IV) 8. Site Master File 9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
8. Site Master File 9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
9. Validation Master File 10. Proposed flight route, including connecting flights (if any)						
10. Proposed flight route, including connecting flights (if any)						
Litetal superation [Details required:						
 i) Hotel Name, ii) Hotel Rate Per Night iii) Official Website, iv) Distance between hotel and manufacturing facility 	 ii) Hotel Rate Per Night iii) Official Website, iv) Distance between hotel and manufacturing facility 					
12. Entry requirements to the destination country for Malaysian citizens	v) Accommodation during transit (if any)					
Declaration letter from manufacturer stating that the premise is ready to be inspected at						
Valid GMP evidence (preferably GMP certificate/report issued by a PIC/S Participating Authority)						
 If company is eligible for <u>GMP DESKTOP ASSESSMENT (GDA)</u> (refer GDA acceptance criteria as mentioned below), the <u>ADDITIONAL</u> following documents (15-22) <u>MUST</u> be submitted together with this application (<i>Soft copy</i>). GDA acceptance criteria: Manufacturing sites inspected by NPRA previously with an acceptable GMP status for the same dosage form(s) Applicable for sterile and non-sterile facilities (excluding biopharmaceuticals) Application of NPRA/431/11 is submitted at least 1 year before the expiry of GMP status (3 years after the last inspection date) for 1st GDA application For 2nd GDA application, NPRA/431/11 is submitted at least 1 year before GMP validity extension from the 1st GDA approval. 						
GMP evidence by National Pharmaceutical Regulatory Agency (NPRA) i.e. GMP certificate						
15.GMP evidence by National Pharmaceutical Regulatory Agency (NPRA) i.e. GMP certificate16.Regulatory Inspection List (all on-site inspections conducted within the past three years)						
10: regulatory inspection List (an off-site inspections conducted within the past time years) 17: Warning letter or equivalent regulatory action issued by any authority [If none, refer to (16)]						
18. Declaration from manufacturer (on company letter head) for item 15						
19. Product complaint and recall register for the past three years						
20. Change Control, Deviation, Quality Risk Assessment (QRM) register for the past three years	Change Control, Deviation, Quality Risk Assessment (QRM) register for the past three					
21. List of products manufactured within the last 6 - 12 months for the relevant products						
22. GDA Pre-assessment (Please refer to Annex V)						

PART F APPLICANT DECLARATION

- I am hereby authorised by the company to make this application. I undertake to pay the non-refundable processing fee of RM 5,000 upon application and inspection fee of RM 20,000 at least one month before the foreign inspection is conducted using a banker's cheque payable to BAHAGIAN REGULATORI FARMASI NEGARA. Alternatively, payment can also be made directly at the Seksyen Kewangan, Akaun dan Hasil (SKAH) counter, NPRA via credit or debit cards. [Note: Only complete application form with confirmed payment will be processed by NPRA]
- 2. I have read and understood the contents of the Drug Registration Guidance Document and Guidance Document Foreign GMP Inspection.
- 3. I hereby declare that details furnished on this form are true, accurate and complete; the supporting documents are authentic or true copies and undertake to notify NPRA, in writing, within one week of any changes in the particulars submitted in this application.
- 4. I understand that the final decision on performing GDA is based on the acceptance criteria stated in Part E and screening process through GMP Desktop Assessment Selection Tools (GDAST).
- 5. I undertake to pay all required inspection expenses which include flight ticket, accommodation, and other associated expenses (such as allowances, insurance, etc.) if inspection is required by NPRA. I shall make the payment in the form of contribution into

		FOREIGN GIVIP	INSPECTION APPLICATION FORM
	dan Pemeriksaan APB (Main Code: 8863 Name : KETUA		
	I undertake to add more contribution to the in the event where the foreign inspection of I understand that the remainder of the cor Amanah Penilaian, Pengiktirafan Akredita I hereby confirm that the foreign manufact I undertake to ensure that the medicinal pen NPRA. I confirm that the new products to be region owner.	e trust fund if the expenses for the inspect cannot be conducted, the contribution with the trust fund in the trust fund usi dan Pemeriksaan APB. turer has agreed and is ready to be inspect roducts are manufactured in accordance stered in Malaysia are licensed/certified anditions stated in the current Guidance I	d for future purposes as outlined in the Arahan
	(Signature)	(Date)	(Company Stamp)
	(Name & Designation)		
PAF	ADDITIONAL DECLARATIO	N (only applicable if the facility is manufactu	ring registered products for other PRH)
1. 2.	nfirm that: The information stated in Annex IV is true, All the other PRH are aware and understan products manufactured at this facility.		tion may affect the registration status of all the
	(Signature)	(Date)	(Company Stamp)

(Name & Designation)

	ANNEX I (Details of new products to be registered in Malaysia)				
No.	Product Name (Reference No If any)	Active Ingredient	Dosage Form	The product is licensed/certified for sale in the country of manufacture/product owner (Yes/No)	

ANNEX II (Details of existing registered products for renewal of product registration)				
No.	Product Name	Registration Number	Registration Period	

	ANNEX III (Details of existing registered products for change of manufacturing site)				
No.	Product Name	Registration Number	Registration Period	Current Manufacturer Name & Address	

	ANNEX IV (Details of product registration holder and their respective registered products)				
No.	Product Registration Holder	Product Name	Registration Number		

ANNEX V (GDA Pre-assessment)				
No.	GDA Parameters of Pre-assessment	Please ⊠ only one		
		More than 150 employees		
1.	Number of employees.	□ 50 – 150 employees		
		Less than 50 employees		
	—	More than 7 processes		
2.	The maximum number of different manufacturing/ distribution process.	□ 4 – 6 processes		
		□ 1 – 3 processes		
	The level of dedication of equipment and facilities that	No dedication		
3.	is in place at the site (for e.g. No dedication, partial	Partial dedication		
	dedication, full dedication).	Full dedication		
4.	Involvement of Real Time Release Testing (RTRT)	Real Time Release Testing (RTRT) activities		
4.		No Real Time Release Testing (RTRT) activities		
	Complexity of products manufactured (for e.g.: low concentration/high potency, sustained release, normal product, biological).	Complex product type (low concentration / high potency, sustained release)		
5.		Normal product		
		Repacking only		
	The maximum number of unit operations in a non-			
6.	sterile manufacturing process (e.g. dispensing, mixing, granulate, drying, coating, blister, packing, testing,	 More than 6 processes 4 – 5 processes 		
0.		Less than 3 processes		
	IPQC)	 Packing of products for clinical trials, primary 		
	Involvement of repackaging activities (for e.g. primary,	repack		
7.	secondary).	Secondary repack		
		No repack activities		
	Engagement of sub-contract activities (for e.g. contract lab, transport). *Can tick more than one	 Subcontracting of processes / stages of manufacturing, primary packaging and QC 		
8.		Subcontracting services: contract lab, transport etc.		
		□ No subcontracting		
9.	The maximum number of components in a product, include final pack (for e.g. vial, diluent, syringe, leaflet).	More than 4 components		
		□ 2 – 3 components		
		□ 1 component (primary packaging)		
		Cold chain, shorter shelf life		
10.	Any product with specific storage requirement. *Can tick more than one	Specified storage requirement		
		No specific storage requirement		

*Please refer to Guidance Document for Foreign Inspection (Appendix 3) for the description of the parameters.